Results 111 to 120 of about 20,028 (211)

PCSK9 and Breast Cancer Survival: A Mendelian Randomization Study. [PDF]

Cancer Epidemiol Biomarkers Prev
Pott J, Mason AM, Salo V, Kettunen J, for FINNGEN, Burgess S.   +5 more
europepmc   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. [PDF]

Circulation
Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, Hochdörfer T, Bergenholm L, Töppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Lindén D, Rosenmeier JB.   +28 more
europepmc   +1 more source

Knowledge, Attitudes, and Practices Regarding PCSK9 Inhibitors Among Healthcare Professionals: Exploring Behavioral Pathways and the Intermediary Role of Attitude. [PDF]

J Multidiscip Healthc
Zhao C, Wang N, Shen D, Zhu L, Chen G.
europepmc   +1 more source

Phenolic Compounds with PCSK9 Secretion Inhibitory Activities from the Fruits of <i>Liriope spicata</i>. [PDF]

ACS Omega
Zheng R, Seo MH, Park CW, Ryu GM, Huh J, Choi YH, Whang WK, Chin YW.   +7 more
europepmc   +1 more source

PCSK9 Inhibitor Use and the Risk of Age-Related Macular Degeneration in Patients with Atherosclerotic Cardiovascular Disease. [PDF]

Pharmaceuticals (Basel)
Tsai HR, Hsu JZ, Loh CH, Huang HK.
europepmc   +1 more source

Association Between PCSK9 Inhibitor Use and Risk of Age-Related Macular Degeneration. [PDF]

Transl Vis Sci Technol
Tsai CY, Weng CH, Tsai CY, Sheen YJ, Chen JP, Chen HM, Wang IJ, Chou CC.   +7 more
europepmc   +1 more source

PCSK9 [PDF]

, 2019
openaire   +1 more source

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. [PDF]

J Lipid Res
Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA.   +16 more
europepmc   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +1 more source